Accessibility Toolbar

Bascom Palmer Eye Institute

Avastin, Lucentis proven equally effective - Bascom Palmer ophthalmologist advocates global reform

April 28, 2011

A federal funded study finds that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug, Lucentis, for the treatment of AMD. The results are being reported following the first year of a two-year, multi-center study involving 1,185 patients treated at 43 clinical centers in the United States. The report, from the Comparison of AMD Treatments Trials (CATT), was published online in the New England Journal of Medicine today, April 28, 2011 and will be in the May 12 print edition.